NCT00326326已完成2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 84
- 试验地点
- 31
- 主要终点
- HDL-C Safety and Efficacy
研究概览
简要总结
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
- •Triglycerides between 150-500 mg/dL
- •Fasting Plasma Glucose 140-240 mg/dL
排除标准
- •Known cardiovascular, carotid, or peripheral vascular disease
结局指标
主要结局
HDL-C Safety and Efficacy
次要结局
未报告次要终点
研究者
研究点 (31)
Loading locations...
相似试验
终止
2 期
MK0859 Dose-Ranging Study (0859-003)Mixed HyperlipemiaHypercholesterolemiaNCT00325455Merck Sharp & Dohme LLC500
已完成
2 期
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A StatinHypercholesterolemiaNCT01592240Pfizer354
进行中（未招募）
2 期
A Study in Patients With Mixed DyslipidemiaMixed DyslipidemiaNCT06497127Shanghai Argo Biopharmaceutical Co., Ltd.145
已完成
2 期
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese SubjectsHypercholesterolemiaNCT02055976Pfizer218
已完成
3 期
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemiaNCT00092625Organon and Co442